Aimei Health Technology Reports $83,144 Net Loss for Q2 2026 Amid Increased Costs

Aimei Health Technology Co., Ltd. reported a net loss of $83,144 for the three months ended June 30, 2026, compared to a net income of $424,970 for the same period in 2025. For the six months ended June 30, 2026, the company recorded a net loss of $37,704, a significant decline from the net income of $609,632 reported in the prior year. The losses were primarily attributed to increased general, administrative, and operational costs, which rose to $192,348 for the second quarter of 2026, compared to $41,604 in the same quarter of 2025. Interest income from cash held in the Trust Account also decreased, totaling $109,204 in the latest quarter, down from $466,574 a year earlier.

The company's total assets as of June 30, 2026, amounted to $12,532,359, an increase from $12,103,039 at the end of 2025. This growth was driven by an increase in cash held in the Trust Account, which rose to $12,488,393 from $12,100,110. However, total liabilities also increased to $4,528,684 from $4,061,660, largely due to higher accrued expenses and extension loans from related parties. The company's working capital deficit stood at approximately $3,794,718 as of June 30, 2026.

In terms of strategic developments, Aimei Health has been actively pursuing a business combination but has faced challenges. The company entered into a Business Combination Agreement with United Hydrogen Group Inc. in June 2024, which was later terminated on July 7, 2026, due to the lack of necessary approvals from regulatory authorities. Despite this setback, Aimei Health continues to evaluate potential business combination opportunities and aims to identify a suitable target for future mergers or acquisitions.

Operationally, Aimei Health has not yet commenced any revenue-generating activities, as it remains in the pre-operational phase. The company has focused on organizational activities and preparing for its initial business combination. As of June 30, 2026, Aimei Health had 2,126,000 ordinary shares issued and outstanding, with 1,040,332 shares subject to possible redemption. The company has also engaged in monthly extension loans to prolong the time available for completing a business combination, reflecting its ongoing efforts to secure a viable merger partner.

Looking ahead, Aimei Health's management has expressed concerns regarding its ability to continue as a going concern if it fails to complete a business combination within the prescribed timeframe. The company has until December 6, 2026, to finalize a merger, and it is actively seeking opportunities that align with its focus on healthcare innovation. The outcome of these efforts will be critical for the company's future financial stability and operational viability.